NCT04979884View on ClinicalTrials.gov

Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital

PHASE3CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

January 3, 2022

Primary Completion Date

September 9, 2022

Study Completion Date

December 9, 2022

Conditions
COVID-19 Acute Respiratory Distress SyndromeCytokine Release SyndromePulmonary Fibrosis
Interventions
DRUG

cyclosporine

Dose of Cyclosporine oral capsule of 6 mg/kg/day divided into two doses with normal kidney function for 8-14 days

Trial Locations (1)

21523

Alexandria university, Alexandria

All Listed Sponsors
collaborator

Science and Technology Development Fund (STDF), ,Egypt

UNKNOWN

lead

Alexandria University

OTHER

NCT04979884 - Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital | Biotech Hunter | Biotech Hunter